神州細胞(688520.SH):前三季度預計實現營收6.5億元、同比增長6373.77%
格隆匯10月23日丨神州細胞(688520.SH)公佈,預計2022年前三季度實現營業收入約65034.21萬元,與上年同期相比,將增長約64029.63萬元,同比增長6373.77%左右。
預計2022年前三季度實現歸屬於母公司所有者的淨虧損約40262.08萬元,與上年同期相比,將減少虧損約25812.19萬元,同比減少39.07%左右;
預計2022年前三季度實現歸屬於母公司所有者扣除非經常性損益後的淨虧損約31030.32萬元,與上年同期相比,將減少虧損約36622.33萬元,同比減少54.13%左右。
公司2022年前三季度預計實現營業收入約6.5億元,主要來自公司自主研發的首個產品安佳因®(SCT800,重組人凝血因子VIII)的銷售收入,安佳因?在2021年7月底獲批上市後,開始持續產生銷售收入。2022年前三季度銷售額實現穩步增長,第三季度銷售收入環比增長約24.58%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.